Literature DB >> 3488377

Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer.

K Koizumi, G L DeNardo, S J DeNardo, M T Hays, H H Hines, P O Scheibe, J S Peng, D J Macey, N Tonami, K Hisada.   

Abstract

A conceptual biologic model was developed and used to analyze the behavior of 123I-Lym-1 monoclonal antibody against African human B cell lymphoma in patients with B cell lymphoma. Originally, the observed data could not be simulated with parameters for homologous immunoglobulins reported in the literature because of a major processor that was capable of distinguishing this murine immunoglobulin from the patient's own immunoglobulins. With a nonlinear parametric model, the data observed in patients could be fitted to the model. The nonlinear parameter determined the transfer of antibody from the intravascular to a processor compartment, primarily the liver. This transfer was a function of the number of free receptors in the processor. Model simulated curves for the time course of concentration of antibody in the blood for different amounts of injected antibody revealed that blood clearance of radiolabeled antibody was profoundly decreased by increased amount of injected antibody. This model provides an explanation for the observations that tumor imaging is improved with injection of larger amounts of antibody, and a basis for modifying the pharmacokinetic behavior of an antibody in order to optimize radioimmunodiagnosis and radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488377

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Optimal tumor targeting by antibodies: development of a mathematical model.

Authors:  M J Chappell; G D Thomas; K R Godfrey; A R Bradwell
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

Review 2.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 3.  Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?

Authors:  Abdullah Al Shoyaib; Sabrina Rahman Archie; Vardan T Karamyan
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

4.  Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.

Authors:  J M Trang; A F LoBuglio; R H Wheeler; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

5.  Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  Y Tokuda; T Watanabe; Y Omuro; M Ando; N Katsumata; A Okumura; M Ohta; H Fujii; Y Sasaki; T Niwa; T Tajima
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.